| General Information of Drug Metabolite (DM) (ID: DM001422) |
| DM Name |
1,4-Diiminoquinone intermediate
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2C9 (CYP2C9)
|
DME0019
|
| Oxidation - Two-Electron Oxidation |
Binimetinib
|
[1] |
|
Cytochrome P450 2D6 (CYP2D6)
|
DME0009
|
| Oxidation - Two-Electron Oxidation |
Binimetinib
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - Two-Electron Oxidation |
Binimetinib
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Binimetinib |
DR0214
|
Approved |
Melanoma |
|
|
| References |
| 1 |
Binimetinib Is a Potent Reversible and Time-Dependent Inhibitor of Cytochrome P450 1A2 Chem Res Toxicol. 2021 Apr 19;34(4):1169-1174. doi: 10.1021/acs.chemrestox.1c00036.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
